Drug intelligence / Profile preview

MPN-anti-KRAS (G12D)

Development stage: Preclinical
Lead developer: Libera Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

MPN-anti-KRAS (G12D), also known as LIB111, is a therapeutic candidate developed by LiberaBio. It consists of a monoclonal antibody specifically targeting the KRAS G12D mutant protein, encapsulated within LiberaBio's proprietary Multifunctional Polymeric Nanoparticle (MPN) technology. This delivery system is designed to overcome the challenge of targeting intracellular proteins with large biologics, allowing the antibody to reach and inhibit KRAS G12D within the cytoplasm of cancer cells. The program is currently in the IND-enabling stage for the treatment of KRAS G12D-mutated cancers, such as pancreatic, colorectal, and lung cancers.

Other names: MPN-anti-KRAS (G12D)

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on MPN-anti-KRAS (G12D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPN-anti-KRAS (G12D).

Explore the full profile